Anhedonia is a significant factor in substance use disorders, particularly when comorbid with depression, and negatively affects treatment outcomes.
Answers are grounded in this paper and cite their sources.
May warrant anhedonia assessment in SUD with depression; leaves open whether targeting it improves outcomes.
Anhedonia is associated with substance use disorders, and their severity is especially prominent in DUS with comorbid depression. Anhedonia may be both a trait and a state dimension in its relation to DUS and tends to impact DUS treatment outcome negatively.
No takes yet. Share an insight, caveat, or question.
Destoop et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: